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pAbstract
Background: Impaired coagulation contributes to the morbidity and mortality
associated with septic shock. Whether abnormal platelet contraction adds to the
bleeding tendency is unknown. Platelets contract when Ca2+-dependent myosin light
chain kinase (MLCK) phosphorylates Ser19 of myosin light chain (MLC20), promoting
actin-myosin cross-bridge cycling. Contraction is opposed when myosin light chain
phosphatase (MLCP) dephosphorylates MLC20. It is thought that Rho kinase (ROK)
inhibits MLCP by phosphorylating Thr855 of the regulatory subunit MYPT, favouring
platelet contraction. This study tested the hypotheses that in septic shock, (i) platelet
function is inversely correlated with illness severity and (ii) ROK-dependent MLCP
inhibition and myosin light chain phosphorylation are reduced.
Methods: Blood was sampled from non-septic shock patients and patients in the first
24 h of septic shock. Platelet function was assessed using whole blood impedance
aggregation induced by 1) ADP (1.6 and 6.5 μM), 2) thrombin receptor-activating protein
(TRAP; 32 μM), 3) arachidonic acid (500 μM) and 4) collagen (3.2 μg/ml). Arachidonic
acid-induced aggregation was measured in the presence of the ROK inhibitor Y27632.
Illness severity was evaluated using sequential organ failure assessment (SOFA) and
acute physiology and chronic health evaluation (APACHE) II scores. Western blot
analysis of [Ser19]MLC20 and [Thr855]MYPT phosphorylation quantified activation
and inhibition of platelet MLC20 and MLCP, respectively. Data were analysed using
Spearman's rank correlation coefficient, Student's t-test and Mann-Whitney test;
p < 0.05 was considered significant.
Results: Agonist-induced aggregation was attenuated in septic shock patients (n = 22
to 34; p < 0.05). Aggregation correlated inversely with SOFA and APACHE II scores
(n = 34; p < 0.05). Thr855 phosphorylation of MYPT from unstimulated platelets was
not decreased in patients with septic shock (n = 22 to 24). Both septic shock and ROK
inhibition attenuated arachidonic acid-induced platelet aggregation independent of
changes in [Ser19]MLC20 and [Thr855]MYPT phosphorylation (n = 14).
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Conclusions: Impairment of whole blood aggregation in patients within the first 24 h of
septic shock was correlated with SOFA and APACHE II scores. Attenuated aggregation
was independent of molecular evidence of diminished platelet contraction or reduced
ROK inhibition of MLCP. Efforts to restore platelet function in septic shock should
therefore focus on platelet adhesion and degranulation.
Keywords: Platelets; Sepsis; Shock; Aggregation; Rho kinase; Myosin phosphatase; Whole
blood impedance aggregometry; Illness severity score
Background
Septic shock is fatal in over 20% of cases in the developed world [1,2]. Coagulation
abnormalities are common in septic shock, ranging from mild thrombocytopaenia to
disseminated intravascular coagulation. Whilst thrombocytopaenia is established as
occurring frequently and of prognostic importance in sepsis [3], the nature of qualitative
changes in platelet function remains incompletely understood.
Analysis of platelet function in the context of infection and sepsis has yielded equivocal
data depending on the experimental paradigm. When platelets isolated from healthy volun-
teers are exposed to bacterial lipopolysaccharide (LPS) [4-7] or lipoteichoic acid (LTA) [8],
or sepsis-associated cytokines [9], aggregation has been shown to be enhanced, inhibited or
unchanged. In contrast, platelets isolated from septic shock patients show a profound and
consistent reduction in adhesion and aggregation response to a range of agonists [10-13],
despite biochemical evidence of increased platelet activity [14,15]. This suggests an intrinsic
abnormality of a common effector pathway - adhesion, secretion or contraction - that
persists even when the platelet is removed from the septic milieu. Considerable effort has
investigated the role of abnormal platelet adhesion; however, the integrity of platelet
contraction has not been specifically assessed in the context of sepsis or septic shock.
Activated platelets contract with similar force to muscle - by making the clot more
rigid and adherent, the platelet maintains clot shape and promotes uniform retraction
[16]. Platelet contraction is determined by two opposing enzymatic processes (illustrated
in Figure 1): (i) myosin light chain kinase (MLCK) phosphorylates Ser19 of myosin
regulatory light chain (MLC20) [17,18] to promote actin-myosin cross-bridge cycling
and contraction [19]; (ii) myosin light chain phosphatase (MLCP) dephosphorylates
[Ser19]MLC20, uncoupling actin and myosin and favouring relaxation [20]. MLCK is
stimulated by increased cytosolic Ca2+ derived either from the extracellular space [21]
or from intracellular Ca2+ stores [22]. MLCP has been reported to be regulated by
two mechanisms: (i) RhoA activates Rho kinase (ROK) [23] which inhibits MLCP by
phosphorylating [Thr855]MYPT, the regulatory subunit of MLCP [24-26]. (ii) Activated
PKC phosphorylates [Thr38]CPI-17 which directly and specifically inhibits MLCP
[24,27-29]. By inhibiting MLCP, both RhoA/ROK and PKC/CPI-17 activities favour
contraction, potentially explaining how platelets can be stimulated to change shape in
the absence of significant changes in cytosolic [Ca2+]in [30,31] and why aggregation is
attenuated in platelets lacking the Gα13 (RhoA activating) subunit [32].
Previous studies have evaluated aggregation of platelets from patients with sepsis;
however, our analysis of platelet function was restricted to patients with septic shock.
Since septic shock is characterised by uncontrolled vasodilation and recognising that
vascular smooth muscle and platelets may share common contractile signalling pathways
Figure 1 Platelet aggregation requires contraction, adhesion and secretion. ROK promotes platelet
aggregation independent of MLCP inhibition. Platelet contraction requires Ser19 myosin light chain (MLC20)
phosphorylation by Ca2+:calmodulin (CaM)-dependent myosin light chain kinase (MLCK). Agonists such as
arachidonic acid initiate platelet contraction by augmenting [Ca2+]cyt derived from both the extracellular
fluid via transient receptor potential (TRP) channels and intracellular dense tubular system stores. Contraction
is opposed when MLC20 is dephosphorylated by myosin light chain phosphatase (MLCP). It is proposed that
MLCP is regulated by two mechanisms: (i) G protein-coupled receptors (GPCRs) bearing the Gα13 subunit
activate membrane-bound RhoA, which activates Rho kinase (ROK) [23]; ROK is thought to inhibit MLCP by
phosphorylating Thr855 on MYPT, the regulatory subunit of MLCP [24-26] (dashed line). (ii) PKC-dependent
CPI-17 directly inhibits MLCP [24,27-29] (not shown). By inhibiting MLCP, both ROK and CPI-17 favour contraction
independent of the prevailing [Ca2+]. Other than disinhibiting MLCP, there are other mechanisms by which ROK
inhibition might oppose platelet aggregation: ROK is also involved in vesicle trafficking and degranulation,
pseudopodium formation, stabilisation of platelet-fibrin binding and actin polymerisation.
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smooth muscle contraction and platelet contraction. Contractile dysfunction in vascular
smooth muscle has been associated with increased MLCP activity in animal models of
sepsis. In particular, inhibitory [Thr855] phosphorylation of MYPT (the target of
RhoA/ROK) is reduced in both an endotoxaemic rat model [35] and a caecal ligation
and puncture mouse model [36].
Both whole blood impedance aggregometry and Western blot analysis of P-[Ser19]
MLC20 and the ROK substrate P-[Thr855]-MYPT were performed to test the following
hypotheses: 1) whole blood aggregation of platelets is attenuated in patients with septic
shock, 2) platelet aggregation in septic shock patients correlates with illness severity
indexed by the SOFA and APACHE II scores, and 3) platelet aggregation in septic shock
patients is associated with reduced (i) [Ser19]MLC20 phosphorylation and (ii) RhoA/
ROK-mediated inhibition (Thr855 phosphorylation) of myofilament-associated MLCP.
The integrity of platelet contraction and its potential as a therapeutic target is an




This prospective observational study was approved by the research ethics committees of the
University of Adelaide and the Royal Adelaide Hospital. Consecutively identified patients
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the intensive care unit of the Royal Adelaide Hospital on randomly allocated sampling days
between September 2012 and May 2013 meeting the eligibility criteria were enrolled into
the study; 40 patients were recruited with acute (<24 h) septic shock, and 40 patients were
recruited into the non-septic shock control group. The diagnosis of septic shock was
defined as the presence of two or more of the following: (i) temp >38°C or <36°C, (ii) heart
rate >90 bpm, (iii) respiratory rate >20 or PaCO2 <32 mmHg, (iv) leucocyte count >12,000
or <4,000/mm3 or >10% bands, plus suspected or proven source of infection, organ dysfunc-
tion attributable to sepsis and hypotension/requirement for vasopressor support >1 h
despite adequate fluid resuscitation. Patients were managed according to current inter-
national guidelines [37]. These diagnostic criteria were absent in control patients who were
post-operative elective surgical patients in whom an indwelling arterial catheter had been
sited for routine intra-operative monitoring. Because agonist-induced platelet aggregation
has been shown to be enhanced beyond 24 h after surgery [38], samples were drawn a
maximum of 8 to 12 h post surgery. Exclusion criteria included co-incident malignancy,
pre-existing platelet abnormality, patients receiving anti-platelet medications or platelet
transfusions over the last 28 days, patients undergoing extracorporeal membrane oxygen-
ation or admission within the last 72 h with severe trauma. Patients with platelet
count <150,000/μl (measured max 4 h before sampling or at the time of sampling) were
excluded from functional analysis.
Blood samples were taken and demographic and clinical data were recorded from all
patients enrolled in the study after written informed consent was acquired from pa-
tients or their next of kin.Illness severity
Illness severity was evaluated using two different composite scoring tools: the sequen-
tial organ failure assessment (SOFA) and acute physiology and chronic health evalu-
ation (APACHE) II scores. The former incorporates respiratory, cardiovascular,
neurological, liver, renal and coagulation (including platelet count) parameters [39];
the latter incorporates age, previous health status and 12 acute cardiovascular, respira-
tory, neurological, haematological and renal parameters (notably platelet count is not
included) [40].Sample preparation
A volume of 12 ml of blood was drawn from an existing arterial line into 3.2% sodium
citrate tubes (VACUETTE®, Greiner Bio-One, Kremsmünster, Austria). Samples were
partitioned to be analysed either by whole blood impedance aggregometry or to
undergo protein extraction for Western blot analysis of the phosphorylation state of
[Ser19]-MLC20 and [Thr855]-MYPT.Platelet aggregation
Whole blood impedance aggregometry (Multiplate® aggregometer, Dynabyte, Munich,
Germany) was performed within 1 h of blood collection according to the manufacturer's
instruction. Samples were not normalised by platelet concentration since Multiplate
whole blood impedance aggregometry by the Multiplate system has been shown to be
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Citrated whole blood (300 μl) was diluted with physiological saline (300 μl; 37°C) followed
by incubation for 3 min at 37°C. Following administration of agonists, platelet aggregation
(measured in aggregation units (AU)) was recorded for 6 min. Aggregation recording was
repeated if the area under the curve detected by each of the two electrodes varied more
than 20% from the mean. As a further control to exclude the influence of platelet count
on aggregation response, results of aggregation induced by adenosine diphosphate (ADP;
6.5 μM) and arachidonic acid (500 μM) were plotted against platelet count for samples
from both septic shock and non-septic shock patients; no correlation was found (n = 34,
p > 0.05; data not shown).
In order to ascertain whether there was a generalised impairment of platelet aggre-
gation that was consistent with a reduction in [Ser19]MLC20 and [Thr855]MYPT
phosphorylation-dependent contractility, the aggregation response to agonists was
measured: thrombin receptor-activating protein (TRAP; 32 μM) and arachidonic acid
(500 μM), both associated with RhoA/ROK-mediated inhibition of MLCP, and ADP
(1.6 and 6.5 μM) and collagen (3.2 μg/ml), which are RhoA/ROK independent [aggre-
gation agonists purchased were sourced from Multiplate®] [42].
In order to identify whether platelet aggregation was impaired by inhibition of the
RhoA/Rho kinase pathway, the aggregation response to arachidonic acid was also mea-
sured in the presence or absence of 20 min of incubation with the Rho kinase inhibitor
Y27632 (1 μM) [(1R,4r)-4-((R)-1-aminoethyl)-N-(pyridin-4-yl)cyclohexanecarboxa-
mide, Calbiochem-Novabiochem Corp., San Diego, CA, USA] and Y27632 alone.
Additional controls included aggregation responses of platelets incubated in buffer alone
or Y27632 alone.
Western blot analysis
To identify whether the reduction in aggregation of platelets from patients suffering
from septic shock was associated with reduced activity of the contractile proteins,
Western blot analyses were used to measure the state of MLC20 phosphorylation (P-
[Ser19]MLC20) in 1) unstimulated platelets, 2) arachidonic acid-stimulated platelets,
3) arachidonic acid-stimulated platelets pre-incubated with Y27632 for 20 min and
4) platelets incubated with Y27632 only. To address whether the P-[Ser19]-MLC20
was associated with altered RhoA/ROK-dependent Ca2+ sensitivity, the Thr-855
phosphorylation state of the MYPT P-[Thr855]MYPT targeting subunit of MLCP
was directly measured in the same platelets. Results were compared for platelets
from both non-septic and septic shock patients.
Since no increase in Thr855 phosphorylation of platelet MYPT has been specifically
identified in the literature, we used a comparison of unstimulated and TxA2 receptor
agonist (U46619)-stimulated rat mesenteric artery as a positive control [24]; rat caudal
artery samples were transferred with the platelet samples.
Briefly, platelet-rich plasma was isolated by centrifuging 2 ml of whole blood at 800
rpm (in an Eppendorf microfuge) for 12 min and decanted. The platelet-rich plasma
was then stimulated with arachidonic acid (500 μM), Y27632 (1 μM) or both before
being centrifuged at 2,600 rpm for 18 min to yield a platelet-rich pellet. The plasma
was discarded and the platelet-rich pellet washed three times in phosphate-buffered
saline. Enzymatic activity in platelets was stopped by incubating for 30 s in a solution
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three times with ice-cold acetone to remove residual TCA.
A washed platelet-rich pellet from 2 ml of whole blood was solubilised in 200 μl
glycerol-free sample buffer containing 50 mM Tris-HCl, pH 6.8, 1% (w/v) SDS,
1× cOmplete™ protease inhibitor cocktail (Roche, Basel, Switzerland), 100 μM
di-isopropylfluorophosphate (Sigma-Aldrich, Castle Hill, Australia), 10 mM DTT,
20% (w/v) sucrose and 0.1% (w/v) bromophenol blue. Samples were heated to 95°C
for 5 min and then vortex mixed for 90 s. Samples were centrifuged in a microfuge
at 12,000 rpm for 4 min to remove insoluble particulates prior to SDS/PAGE using
Bio-Rad 4–15% Criterion TGX precast gels run in a Bio-Rad Criterion unit at 200 V
for 60 min (Bio-Rad, Hercules, CA, USA). Gels were stained with Coomassie Brilliant
Blue R-250 (Merck and Co., Macquarie Park, Australia) and scanned using the LI-
COR Odyssey system (LI-COR Biotechnology, Lincoln, NE, USA) to quantify the total
extracted protein and allow normalisation of total protein content in the samples. Fol-
lowing normalisation of extracted protein content in samples, SDS/PAGE was re-
peated and proteins were electrophoretically transferred onto 0.22 μm nitrocellulose
(Bio-Rad) (100 V for 30 min) in transfer buffer containing 25 mM Tris/HCl, 192 mM gly-
cine, 20% (v/v) methanol and 0.1% (w/v) SDS for MYPT and without SDS for MLC20. Fol-
lowing protein transfer to nitrocellulose, non-specific binding sites were blocked with a
solution containing 50% LI-COR Odyssey™ blocking buffer/50% Tris-buffered saline
(TBS; 50 mM Tris, pH 7.4, 150 mM NaCl) for 60 min, followed by incubation with TBS
plus 0.05 Tween-20 (TBS-T) containing either mouse anti-MYPT1 (1:1,000) [made in-
house [24]], rabbit anti-P-[Thr855]MYPT1 (1:1,000) [Upstate/Millipore USA, Inc., Biller-
ica, MA, USA], mouse anti-MLC20 [Santa Cruz Biotechnology, Santa Cruz, CA, USA] or
mouse anti-P-[Ser19]MLC20 (1:1,000). The nitrocellulose was washed three times in TBS-
T and incubated in TBS-T with a 1 to 10,000 dilution of biotin-conjugated goat anti-
mouse or goat anti-rabbit secondary antibody [Pierce/Thermo Scientific Australia, Scor-
esby, Australia] for 60 min before another three washes with TBS-T. The nitrocellulose
was then incubated for 60 min in TBS-T with a 1 to 10,000 dilution of streptavidin conju-
gated to the 800-nm DyLight fluorochrome [Pierce/Thermo Scientific Australia]. Fluores-
cence was detected and quantified using the LI-COR Odyssey™ system. All samples were
transferred, incubated and scanned together to ensure identical analysis conditions be-
tween septic shock and non-septic shock patients and between different platelet treat-
ments. All samples used in the analysis were within the linear range of detection.Data analysis
Western blot data was expressed as a ratio of total P-[Thr855]/total MYPT and total P
[Ser19]-MLC20/total MLC20. Sample size was determined by a power analysis based
upon data derived from Western blot analysis of MYPT phosphorylation in vascular
smooth muscle [24]. Statistical analysis was performed using GraphPad Prism v. 6
(GraphPad Software, Inc., La Jolla, CA, USA). Data were tested with the D'Agostino
and Pearson omnibus normality test. All results are presented as the mean ± SEM
where n indicates the number of independent experiments for each treatment. For
parametric and non-parametric data, unpaired Student's t-tests and Mann-Whitney
tests, respectively, were used to compare data between groups. For parametric and
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to compare within-patient agonist/inhibitor responses; p < 0.05 was considered statisti-
cally significant. Asterisks indicate statistically significant differences from control.
Spearman's rank-order correlation coefficient was calculated for the relationships be-
tween (i) noradrenaline dose and platelet aggregation response to arachidonic acid and
ADP, (ii) noradrenaline dose required to achieve the desired mean arterial pressure and
Thr[855] phosphorylation state of MYPT, (iii) SOFA and APACHE II scores and aggre-
gation responses to arachidonic acid and ADP and (iv) SOFA and APACHE II scores
and the Thr[855] phosphorylation state of MYPT. A correlation between TRAP/colla-
gen-induced platelet aggregation and illness severity scores was not performed as the
number of samples was too small. Fisher's test was used to analyse the mortality differ-
ence between the groups. A mixed-effects regression analysis was undertaken (Stata/
MP 13.1) to identify significant interactions between variables and to estimate the over-
all effect of septic shock on platelet aggregation.Results
Patients with septic shock (37) and non-septic shock controls (40) were recruited and
were well matched for demographic characteristics; clinical status at the time of blood
sampling was recorded and represented in Table 1 with clinical outcome data. The
mean platelet count was in the normal range for both septic shock (mean 278; SEM
24.27) and non-septic shock (mean 261; SEM 12.44) patients, consistent with the early
stage of septic shock at which whole blood was acquired [43]. Hospital and ICU mor-
tality was higher (p < 0.01) in septic shock patients.
Platelet aggregation in response to each agonist was significantly attenuated in pa-
tients with septic shock. Compared with platelets from non-septic shock patients,Table 1 Clinical status at the time of blood sampling
Septic shock Non-septic shock
Number 37 40
Age 60.54 ± 13.55 60.5 ± 14.52
Female, n (%) 26 (70) 27 (68)
Smoker, n (%) 12 (32) 8 (20)
APACHE II scorea 24.14 (1.19) NA
SOFA scoreb 9.5 (0.47) NA





Mean catecholamine dose (μg/min) 18.7 (2.03) NA
Platelet count (109/l) 278 (24.3) 261 (12.4)
ICU mortality (%) 10 (27) 0
Hospital mortality, n (%) 16 (43) 2 (5)
Unless otherwise stated, values indicate mean and SEM; p > 0.05 for all comparisons except ICU and hospital mortality,
where p < 0.01. aAcute physiology and chronic health evaluation (APACHE) II score, a higher value indicates greater
admission illness severity. bSequential organ failure assessment (SOFA) scores range from 0 to 24 with higher scores
indicating more severe organ dysfunction. NA, non-applicable.
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ance aggregation in response to low-dose ADP (74.3 ± 8.7 vs. 51.2 ± 6.7), high-dose
ADP (78.1 ± 7.5 vs. 55.5 ± 6.8), thrombin receptor-activating protein (92.4 ± 6.8 vs.
69.3 ± 9.4) and collagen (108.8 ± 9.4 vs. 83.3 ± 11.1) (n = 16 to 20 per patient group, p
< 0.05) (Figure 2). Regression analysis across agonists was used to model the overall ef-
fect of septic shock on aggregation; the overall estimate of the impact of septic shock
on aggregation is −32% (−7.8, −55.7, p < 0.05).
Platelet aggregation was strongly promoted by arachidonic acid. Arachidonic acid-
mediated platelet aggregation was attenuated in whole blood (i) taken from patients
with septic shock and (ii) incubated with the Rho kinase inhibitor Y27632.
Arachidonic acid (500 μM)-mediated platelet aggregation was attenuated in whole
blood taken from patients with septic shock (76.9 ± 6.4 vs. 57.1 ± 7.5; n = 26 to 33,
p < 0.05). To illustrate the proof of principle that ROK inhibition can attenuate platelet
function, platelets were incubated for 20 min with the ROK inhibitor Y27632. Incubation
with Y27632 significantly attenuated arachidonic acid-mediated aggregation in whole
blood from both non-septic shock and septic shock patients (35.3.0 ± 15.4 and 31.3 ±
11.3; n = 10 to 12, p < 0.05.) In the presence of Y27632, arachidonic acid-induced aggrega-
tion was not significantly different from aggregation of unstimulated platelets (13.5 ± 7.1
vs. 15.03 ± 5.0 (non-septic shock) and 11.7 ± 4.8 vs. 11.4 ± 3.6 (septic shock); n = 10 to
12) (Figure 3). Although regression modelling identified a positive interaction between
ROK inhibition and septic shock supporting that the effect of ROK inhibition is lessened
in the presence of septic shock, this was non-significant (p = 0.312).
The regression analysis was repeated controlling for platelet count, the result of which
was consistent with our more simplified analysis and did not change our inference with
respect to the effect of septic shock or ROK inhibition, namely the conclusion that septic
shock was associated with a reduction in platelet aggregation in response to each of four
agonists.Figure 2 Whole blood platelet aggregation is reduced in patients with septic shock. Whole blood
platelet aggregation in response to ADP, thrombin receptor-activating protein (TRAP) and collagen was
attenuated in patients suffering from septic shock (red bar) vs. non-septic shock controls (blue bar). (n = 16
to 20 per patient group, *p < 0.05).
Figure 3 Arachidonic acid-dependent platelet aggregation was reduced in patients with septic
shock. Platelet number was not significantly different between septic shock and non-septic shock patients;
however, arachidonic acid-induced aggregation was reduced in platelets derived from septic shock patients
(red bar) compared with non-septic shock controls (blue bar) (n = 26 to 33 per patient group, p < 0.05).
Incubation for 20 min with the ROK inhibitor Y27632 significantly attenuated arachidonic acid-mediated
platelet aggregation in whole blood from both septic shock and non-septic shock patients. Arachidonic
acid-induced aggregation in the presence of Y27632 was not significantly different from aggregation of
unstimulated platelets. (n = 10 to 12 per patient group, * and † p < 0.05).
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scores. Amongst patients with septic shock, the aggregation response to both ADP (6.5
μM) and arachidonic acid (500 μM) was inversely correlated with their SOFA score
(n = 26, r = −0.51 and −0.36, respectively, p < 0.05; Figure 4A,B). Although the SOFA
score includes platelet count, there was no correlation between platelet count and
SOFA score in septic shock patients in this study and platelet count was similar in both
septic shock and non-septic shock patients (Table 1). Furthermore, ADP- and arachi-
donic acid-induced aggregation correlated inversely with the SOFA score even when
coagulation parameters were excluded (p < 0.05). Furthermore, ADP- and arachidonic
acid-induced aggregation of platelets from septic shock patients was also inversely
correlated with their APACHE II score (n = 26, r =−0.44 and −0.47, respectively, p < 0.05;
Figure 4C,D); the APACHE II calculation does not include platelet count. Platelet aggre-
gation was not significantly correlated with noradrenaline dose or mean arterial blood
pressure (data not shown).
Contraction-associated P-[Ser19]MLC20 was increased in platelets stimulated with
arachidonic acid; this increase was not attenuated in platelets from septic shock patients
or by pre-incubation with Y27632.
Baseline P-[Ser19]MLC20 in unstimulated platelets was not different in platelets from
patients with or without septic shock (0.84 ± 0.27 vs. 0.57 ± 0.14). Following stimulation
with arachidonic acid, P-[Ser19]MLC20 was significantly higher in platelets from both
non-septic shock and septic shock patients (2.0 ± 0.49 and 1.8 ± 0.53; p < 0.05), but the
increase was not significantly different between non-septic shock and septic shock pa-
tients. Pre-incubation with Y27632 did not reduce the arachidonic acid-induced increase
in P-[Ser19]MLC20 in platelets from either patient group (non-septic shock 1.5 ± 0.69 and
septic shock 1.5 ± 0.63). The proportion of P-[Ser19]MLC20 in unstimulated platelets was
A B
C D
Figure 4 Platelet aggregation is inversely correlated with illness severity. There was a significant
correlation (p < 0.05) between sequential organ failure assessment (SOFA) and acute physiology and
chronic health evaluation (APACHE) II scores at the time of blood sampling and platelet aggregation
induced by (A, C) ADP (r = −0.51 and −0.36) and (B, D) arachidonic acid (r = −0.41 and −0.47) in whole
blood taken from patients with septic shock (n = 26). Note: platelet concentration was not significantly
lower in the septic shock patients, and there was no correlation between platelet count and either SOFA
or APACHE II score (p > 0.05).
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0.08 and septic shock 0.52 ± 0.23) (n = 14 per patient group; Figure 5).
The baseline Thr855 phosphorylation state of MYPT was not reduced in platelets
taken from patients with septic shock.
The fraction of the MLCP regulatory subunit MYPT which was phosphorylated at
the inhibitory Thr855 site (i.e. the proportion of MLCP in the putative RhoA/ROK-
dependent inactive state) was not different in unstimulated platelets taken from either
non-septic shock or septic shock patients (6.482 ± 1.32 vs. 7.658 ± 1.07; n = 22 to 24 per
patient group; Figure 6). The Thr855 phosphorylation state of MYPT was not correlated
with the noradrenaline dose, mean arterial pressure or SOFA/APACHE II scores (data not
shown). Control experiments using rat mesenteric artery samples transferred alongside
platelet samples identified that treatment with U46619 (1 μM), a mimetic of the
arachidonic acid metabolite thromboxane A2, increased P[Thr855]MYPT (4.79 ± 1.27
vs. 14.71 ± 2.02) and incubation with Y-27632 (1 μM) attenuated U46619-mediated P
[Thr855]MYPT.
In platelets from both septic shock and non-septic shock patients, the Thr855 phos-
phorylation state of MYPT was not significantly different in platelets stimulated with
arachidonic acid and platelets stimulated with arachidonic acid following incubation
with Y27632.
Figure 5 Neither septic shock nor ROK inhibition reduced arachidonic acid-induced LC20
phosphorylation. Following stimulation with arachidonic acid, Ser19 phosphorylation of LC20 was
significantly increased in platelets from both septic shock (red bar) and non-septic shock control (blue bar)
patients. Pre-incubation with Y27632 did not significantly attenuate the arachidonic acid-induced increase
in Ser19 phosphorylation of LC20. Arachidonic acid-induced Ser19 phosphorylation of LC20 was not different
in platelets derived from patients with septic shock compared to those derived from non-septic shock
controls. (n = 14 to 15 per patient group, *p < 0.05).
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platelets taken from either patient group following stimulation with arachidonic acid
(non-septic shock 25.64 ± 8.16 vs. 22.05 ± 7.06; septic shock 25.27 ± 6.96 vs. 25.52 ±
8.02). There was no significant difference in the Thr855 phosphorylation state of MYPT
in either group following stimulation with arachidonic acid of platelets that had been
incubated with Y27632 (non-septic shock 22.25 ± 5.75 vs. septic shock 18.42 ± 5.91)
(n = 13 to 15; Figure 7).Discussion
The global impact of septic shock is profound; in 2012, the Surviving Sepsis Campaign
Guidelines Committee stated that severe sepsis and septic shock affect ‘millions of people
around the world, killing one in four (and often more), and is increasing in incidence’
[37]. Up to 7% of patients with septic shock experience life-threatening haemorrhage [1];
although thrombocytopaenia contributes to haemorrhage in sepsis and is an independent
risk factor for poor outcome [44], the presence, impact and mechanism of qualitative
platelet dysfunction are less well established. The study tested the primary hypothesis that
whole blood aggregation of platelets from patients with septic shock would be attenuated
and that the degree of aggregation impairment would correlate with illness severity
indexed by the SOFA and APACHE II scores. The secondary hypothesis that reduced
platelet aggregation would be associated with (i) reduced activation of the myosin light
AB
Figure 6 ROK-dependent myosin phosphatase activity was unchanged in platelets isolated from
patients with septic shock. (A) The proportion of the myosin phosphatase regulatory subunit (MYPT)
phosphorylated at the ROK substrate site Thr855 did not differ between unstimulated platelets taken from
patients with septic shock compared to those taken from non-septic shock controls (n = 22 to 24 in each
patient group). (B) Rat mesenteric artery samples were transferred with platelet samples as controls. Treatment
with the stable thromboxane A2 mimetic U46619 increased ROK-dependent Thr855 phosphorylation of MYPT
that was attenuated with the ROK antagonist Y-27632; representative data from n = 3.
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associated MLCP was also tested.
Our data add to the weight of evidence that platelet function is impaired in sepsis
[10,45], identifying for the first time that specifically in human septic shock, there is a
clear reduction in ADP-, thrombin receptor-activating protein-, arachidonic acid- and
collagen-dependent whole blood impedance aggregation.
Platelets are activated when sub-endothelial collagen and the von Willebrand factor
(vWF) are exposed and bind to their respective platelet receptors [46,47]. This triggers
the activation of integrins, which bind platelets to the extracellular matrix. Platelets
then enter a secretion phase, emptying α-granules and dense granules which contain
Figure 7 Thr855 MYPT phosphorylation was not significantly influenced by arachidonic acid, ROK
inhibition or septic shock. The proportion of the ROK substrate MYPT phosphorylated at the inhibitory
Thr855 site was not increased following stimulation with arachidonic acid and/or incubation with Y27632
and did not differ between samples from patients with septic shock (red bar) compared to samples from
non-septic shock patients (blue bar) (n = 13 to 15 per patient group).
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thromboxane A2 (TxA2) de novo [49]. ADP, TxA2 and locally produced thrombin [50]
trigger platelet contraction through heterotrimeric G proteins of the Gq and G13
families [34].
Whole blood impedance aggregometry has advantages over optical-based techniques
[51] since platelets (i) remain in the same humoral and cellular milieu as in vivo, (ii)
do not suffer centrifugation injury, (iii) are analysed sooner after phlebotomy and (iv)
are derived from smaller blood volumes. Whole blood impedance aggregometry thus
permits assessment of platelet function in as close to in vivo conditions as possible.
Generalised attenuation of aggregation to different agonists using independent recep-
tor pathways suggests an abnormality downstream of receptor and second messenger
mechanisms, indicating a failure of one or more of the following: adhesion, secretion or
contraction.
The reduction in agonist-dependent aggregation in patients with septic shock correlated
with higher SOFA (with and without inclusion of the coagulation score) and APACHE II
scores even amongst septic shock patients with relatively preserved platelet counts. The
finding that platelet function provides an early index of disease severity in patients with
septic shock is not surprising since platelets are directly immersed in the milieu of inflam-
matory mediators and bacterial products. This finding warrants further study to identify
whether using whole blood impedance aggregation improves prognostic accuracy in septic
shock.
Platelet aggregation and clot formation depend upon platelet shape change, drawing
the discoid resting platelet into a stiffer structure whilst extending pseudopodia to
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primary haemostatic plug [52]. We postulated that diminished MLC20 phosphorylation,
resulting from reduced ROK-dependent inhibition of MLCP, attenuated platelet con-
traction and hence aggregation in sepsis.
Aggregation of platelets from both non-septic and septic shock patients was pro-
foundly attenuated in the presence of the ROK inhibitor Y27632, demonstrating that,
in principle, if septic shock were associated with impaired ROK-mediated inhibition
of MLCP, this could effectively inhibit platelet aggregation. However, contrary to our
hypothesis, our data show that whilst both septic shock and incubation with a ROK
inhibitor were associated with reduced whole blood aggregation, in neither case was
the attenuation in aggregation associated with a significant reduction in [Thr855]
phosphorylation of MYPT or [Ser19] phosphorylation of MLC20, i.e. attenuation of
aggregation was independent of ROK-mediated inhibition of MLCP or activation of
myosin (dashed line in Figure 1). These data provide two insights: Firstly, reduced
whole blood aggregation in septic shock was independent of molecular evidence of
reduced actin-myosin contraction (no change in myosin LC20 phosphorylation), instead
suggesting impairment of other elements of platelet function such as adhesion or
granule secretion. Consistent with our finding that reduced platelet aggregation in
septic shock was not a consequence of reduced ROK-mediated Thr855 phosphoryl-
ation of MYPT was the observation that aggregation was also attenuated in response
to collagen and ADP, agonists thought to activate platelets independent of Gα12/13
and RhoA/ROK [34].
Secondly, treatment with the ROK inhibitor Y27632 attenuated platelet aggregation
independent of significant changes in the phosphorylation state of [Thr855]MYPT
and phosphorylation of MLC20. There are several alternative mechanisms by which
ROK inhibition might attenuate platelet aggregation independent of changes in
MLC20 phosphorylation [53], and these are illustrated in Figure 1. Specifically, ROK
also (i) maintains active binding of the integrin GPIIbIIIa to fibrin and vWF [54,55],
and it has been identified that activation of GPIIbIIIa is decreased in patients with
sepsis [13]; (ii) mediates vesicle trafficking within platelets independent of MLCP
[56-59]; (iii) is essential for TxA2- and thrombin-induced granule secretion [32,60]
and (iv) modulates actin assembly and polymerisation in the dynamic regulation of
microtubule coils [61-63] and formation of stress fibres [64]. It is now clear that ROK
inhibition may disrupt any of these mechanisms involved in platelet aggregation
without significantly reducing the proportion of phosphorylated [Thr855]MYPT and
[Ser19]MLC20.
Vascular smooth muscle contraction depends on Ca2+-mediated activation of
MLCK and RhoA/ROK-mediated inhibition of MLCP. Animal studies suggest that
diminished contraction of vascular smooth muscle in sepsis is associated with attenu-
ated ROK activity and disinhibition of MLCP [35,36]. Furthermore, common bacterial
pathogens produce toxins capable of inhibiting RhoA/ROK-mediated inhibitory phos-
phorylation of MLCP [65-67] (reviewed by Somlyo and Somlyo [27]). Whilst platelets
also contain ROK, actin-myosin-dependent platelet contraction does not appear to be
mediated by ROK inhibition of MLCP, and septic shock-induced platelet dysfunction
does not appear to be a consequence of platelet contractile dysfunction. Our data
suggest that in patients with septic shock, targeted support of platelet adhesion and
Reddi et al. Intensive Care Medicine Experimental  (2015) 3:5 Page 15 of 17secretion is likely to be of more value in restoring platelet function than targeting
platelet contraction.
Conclusions
Platelets in whole blood derived from patients suffering from septic shock exhibit
reduced aggregation to a range of agonists, indicating an increased bleeding risk despite
a normal platelet count. The reduction in aggregation correlated with illness severity
scores. Therefore, reduced platelet aggregation in whole blood from patients with septic
shock may be valuable as an early prognostic marker associated with poor patient out-
come. Reduced platelet aggregation in patients with septic shock was independent of
molecular evidence of reduced platelet contraction, i.e. [Ser19]MLC20 phosphorylation
or RhoA/ROK-dependent inhibitory phosphorylation of [Thr855]MYPT. Future efforts
to ameliorate coagulopathy in sepsis should consider mechanisms that include platelet
adherence and secretion.
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